Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.